Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
Avalyn's poster presentation at EULAR 2025 will include the Phase 2b study design of AP01 (inhaled pirfenidone) in various forms of progressive pulmonary fibrosis (PPF), including autoimmune ILDs.
EULAR 2025 Poster Presentation:
Title: Inhaled Pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study DesignAuthors: Colin Reisner, Sebastien Tilleux, Allison Trucillo, Deepthi Nair, Felix Woodhead, Howard M. Lazarus, Craig Conoscenti, Martin Kolb
About Avalyn PharmaAvalyn is reimagining the future of pulmonary fibrosis treatment with a pipeline of new inhaled formulations of approved medicines. Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, reduced exercise capacity, and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn's inhaled approach tackles the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs, thereby improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Avalyn's AP01 is an optimized inhaled formulation of pirfenidone, currently being studied in the ongoing MIST Phase 2b study in progressive pulmonary fibrosis (PPF). AP01 has been assessed in over 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety compared to historical data with existing therapies. The company completed two Phase 1 studies for AP02, inhaled nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). For more information, please visit avalynpharma.com and follow us on LinkedIn.
Investor Contact:Alex Straus, THRUST alex@thrustsc.comir@avalynpharma.com
Media Contact:media@avalynpharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2025" report provides a comprehensive insight into worldwide OCD clinical trials. It covers trial numbers, average enrollment, regional data, and sponsor types, enhanced by the proprietary Pharma database. Ideal for strategic decision-making and identifying competitive opportunities. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2025" clinical trials has been added to offering. The clinical trial report provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Countries Contributing to Clinical Trials in Middle East and Africa Top Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Obsessive-Compulsive Disorder Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Appendix Competitive Landscape Roche Holding AG Pfizer Inc Viatris Inc The Lundbeck Foundation Torrent Investments Pvt Ltd Syneos Health Inc AbbVie Inc AstraZeneca Plc Sandoz Group AG Byondis BV For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
New AvidXchange Report Shows Finance Teams More Prepared Than in 2020—But Still Investing to Weather Uncertainty
CHARLOTTE, N.C., July 17, 2025 (GLOBE NEWSWIRE) -- AvidXchange, Inc. a leading provider in accounts payable (AP) automation software and payment solutions for mid-market businesses and their suppliers, today announced the results of its 2025 Economic Sentiment Survey, conducted via Pollfish. The survey of 709 finance professionals reveals a key shift: 67% feel more prepared to handle today's economic uncertainty than they did in 2020, crediting increased technology investment and hard-earned experience. Many are continuing to double down on digital tools to stay agile amid inflation, supply chain disruptions, and ongoing market volatility. Economic Concerns Still Weigh Heavily While confidence is growing, post-Covid hangover remains. 86% of finance professionals express concern about the current state of the economy, with nearly half taking actions like cutting discretionary spending. Additionally, 50% say they are 'very concerned' about the likelihood of a recession, and 22% expect one to hit within the next 12 months. Tariffs and inflation are also reshaping financial planning: 83% report supplier cost increases due to inflation 52% say tariffs have led to moderate forecast adjustments Nearly 1 in 3 organizations are sharing those costs with customers These findings reflect a market still in flux—and the pressure on finance leaders to respond swiftly and strategically. Technology Fuels Financial Readiness Despite uncertainty, tech investments are enabling confidence. Seven in 10 finance professionals say technology is critical to their ability to respond to changing conditions, and 72% say tools implemented early in the pandemic are paying off today. In fact, 49% say they are more likely to invest in AI and automation specifically because of ongoing economic uncertainty. Top areas of focus include: AI and machine learning (48%) Data security and compliance tools (44%) Collaboration and workflow tools (36%) Finance teams are embracing technology not just to cut costs—but to enable smarter, faster decisions. Finance Professionals Emerge as Strategic Partners The survey findings point to a fundamental shift in how finance is viewed: from operational support to strategic leadership. Nearly 30% of teams are conducting scenario planning and financial modeling, while 27% are focused on strengthening supplier relationships—clear signals of a proactive, future-focused mindset. With better tools and a broader mandate, finance leaders are stepping into roles that directly shape business direction, resilience, and growth. Momentum in a Shifting Economy Though 52% of respondents expect volatility to continue into 2026, the overall tone is one of momentum. Finance professionals are moving from reactive to proactive, leaning into their role as stewards of strategy, stability, and innovation. 'Finance teams aren't just adapting—they're planning smarter, automating faster, and driving strategic decisions across the business,' said Dan Drees, President at AvidXchange. 'This research reinforces what we're seeing in the market—technology is a critical enabler for companies looking to drive efficiency and fuel growth.' To read the full report visit About AvidXchange®AvidXchange (Nasdaq: AVDX) is a leading provider in accounts payable (AP) automation, offering intelligent AP software and payment solutions specifically designed for mid-market businesses and their suppliers. With 25 years of industry experience, AvidXchange modernizes the way businesses manage their expenses and payments by offering AI-enhanced software coupled with support from experts. Empowering over 8,500 growth-driven businesses, AvidXchange increases efficiency, control, and visibility in financial operations and has securely processed payments to more than 1.3 million suppliers through its proprietary payment network over the past five years. For more information, visit Media Contact:Alexis RiddickPublic Relations Managerpr@ sesión para acceder a tu portafolio
Yahoo
an hour ago
- Yahoo
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends, market drivers, competitive landscape, and strategies for growth and investment in the NTM market. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast" report has been added to report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems.). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these Highlights Report deliverables include a Pdf report and an Excel-based forecast model Forecast includes the 7 major markets (7MM) Forecast covers the period 2023-2033 Scope Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms. Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period. Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Key Topics Covered: 1. Preface1.1. Contents1.2. Abbreviations1.3. Related Reports2. Executive Summary3. Disease Overview3.1. Overview of NTM3.2. NTM Market SWOT Analysis3.3. Classification of NTM3.4. NTM Risk Factors4. Epidemiology4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-334.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-334.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM5. Current Treatment Options5.1. PNTM Diagnostic Paradigm5.2. Treatment Paradigm5.3. Current Treatment Options6. Unmet Needs and Opportunities6.1. Unmet Needs in NTM6.2. New Therapeutic Options with Improved Efficacy6.3. Improved Diagnostic Methods6.4. Improved Clinical Trials7. R&D Strategies7.1. Trends in Clinical Trial Design in NTM7.2. Trends in Deal-Making in NTM8. Pipeline Assessment8.1. NTM Pipeline Overview8.2. Late-Stage Pipeline Products for NTM8.3. NTM Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. NTM Market Forecast9.2. PNTM Market Forecast9.3. DNTM Market Forecast9.4. Market Drivers and Barriers10. Appendix Competitive Landscape Janssen Novartis AG Meiji Seika Pharma Co Ltd Insmed Inc Daiichi Sankyo Co Ltd MannKind Corp Paratek Pharmaecuticals Inc Nobelpharma Co Ltd GlaxoSmithKline AG Pfizer For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
